Evidence map›Paper›PMID 38361363›Full record

Observational studyHuman vaccines & immunotherapeutics2024

Serological assessment of the durability of vaccine-mediated protection against SARS-CoV-2 infection.

John T Bates, Seth T Lirette, Andrew P Farmer, Michael A Bierdeman, Kristina B Seyfarth, Dallas R Ederer, Denise D Montgomery, Grace C Burnett, Amanda T Pham, Gailen D Marshall

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

John T BatesDepartment of Cell and Molecular Biology, University of Mississippi Medical Center, Jackson, MS, USA.
Seth T LiretteSchool of Population Health, University of Mississippi Medical Center, Jackson, MS, USA.
Andrew P FarmerDepartment of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
Michael A BierdemanDepartment of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
Kristina B SeyfarthDepartment of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
Dallas R EdererMedical Student Research Program, University of Mississippi Medical Center, Jackson, MS, USA.
Denise D MontgomeryDepartment of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
Grace C BurnettDepartment of Cell and Molecular Biology, University of Mississippi Medical Center, Jackson, MS, USA.
Amanda T PhamMedical Student Research Program, University of Mississippi Medical Center, Jackson, MS, USA.
Gailen D MarshallDepartment of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
University of Mississippi Medical Center · USJackson Memorial Hospital · US

Funding

Tracking and Evaluation CoreU54GM115428 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI HALL, JOHN E · 2016 to 2025
$38.2M
Sex differences in operant cocaine memoriesP20GM144041 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI Channabasavaiah Gurumurthy · 2023 to 2026
$12.1M
NIGMS NIH HHS P20 GM144041NIGMS NIH HHS U54 GM115428
6 · The paper itself

Abstract

Virus-neutralizing antibodies are often accepted as a correlate of protection against infection, though questions remain about which components of the immune response protect against SARS-CoV-2 infection. In this small observational study, we longitudinally measured spike receptor binding domain (RBD)-specific and nucleocapsid (NP)-specific serum IgG in a human cohort immunized with the Pfizer BNT162b2 vaccine. NP is not encoded in the vaccine, so an NP-specific response is serological evidence of natural infection. A greater than fourfold increase in NP-specific antibodies was used as the serological marker of infection. Using the RBD-specific IgG titers prior to seroconversion for NP, we calculated a protective threshold for RBD-specific IgG. On average, the RBD-specific IgG response wanes below the protective threshold 169 days following vaccination. Many participants without a history of a positive test result for SARS-CoV-2 infection seroconverted for NP-specific IgG. As a group, participants who seroconverted for NP-specific IgG had significantly higher levels of RBD-specific IgG following NP-seroconversion. RBD-specific IgG titers may serve as one correlate of protection against SARS-CoV-2 infection. These titers wane below the proposed protective threshold approximately six months following immunization. Based on serological evidence of infection, the frequency of breakthrough infections and consequently the level of SARS-CoV-2-specific immunity in the population may be higher than what is predicted based on the frequency of documented infections.

Indexed as

COVID-19VaccinesAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineHumansImmunoglobulin GSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralBNT162 VaccineImmunoglobulin GVaccinesantibody responsebreakthrough infectionSARS-CoV-2vaccinewaning immunity

Identifiers

PMID38361363
PMCPMC10877977
OpenAlexW4391880536

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.